Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Functioning living or deceased donor allograft \>=1 year post-transplantation~* Baseline (screening) biopsy showing Grade II or III interstitial fibrosis/tubular atrophy (IF/TA) (\>=25% IF/TA)~* Progressive loss in kidney function observed after the first year post-transplant, defined as an estimated glomerular filtration rate (eGFR) decline of ≥3 mL/min/year for at least 24 months prior to screening, with a minimum of 2 documented measurements per year (minimum of 4 documented measurements in the 24-month period, performed at least 1 month apart)~* An eGFR \>=30 mL/min/1.73 m\^2 for a period of 6 months up to screening~* Stable standard of care concomitant medication for 3 months prior to screening~* Participant is male or female, \>=18 years of age~Exclusion Criteria:~* Recipient of multi-organ transplant (with the exception of repeated kidney transplant recipients, and/or corneal transplant recipients)~* Screening biopsy shows evidence of significant active antibody-mediated rejection that may affect the conduct of the study (eg, require change in treatment) according to the Principal Investigator (PI)~* Screening biopsy shows evidence of T cell-mediated rejection that may affect the conduct of the study (eg, require change in treatment) according to the PI~* Screening biopsy shows evidence of de novo or recurrent glomerular disease that may affect the conduct of the study (eg, require change in treatment) according to the PI~* Proteinuria ≥1500 mg/g at screening~* Participant who has a history of biopsy-proven acute rejection or treatment for suspected acute rejection within 3 months prior to screening~* Participant has had major surgery (including joint surgery) within 6 months prior to screening, or has planned surgery within 6 months after the last dose of investigational medicinal product (IMP)~* Participant has a current diagnosis of foot ulcer or diagnosis of chronic diabetic ulcer or history of delayed wound healing~* Participant has taken concomitant medication of sirolimus or everolimus within 3 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zampilimab Cohorts (Type: EXPERIMENTAL): Participants will be randomized to receive zampilimab (UCB7858).
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm will receive matching Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).